Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple swab predict who needs less radiation?

NCT ID NCT07718620

Diagnosis Sponsor: Masaryk Memorial Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial is testing a new electrochemical method to monitor HPV infection in patients with head and neck cancers, specifically oropharyngeal carcinoma. The goal is to see if tracking HPV DNA levels during treatment can help personalize therapy, potentially allowing some patients to safely receive less intense radiation. The study compares the new method against standard testing using samples from oral swabs, mouth rinses, and blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HPV p16 diagnostic test using oral swabs, oral cavity washings, and blood samples
What this could lead to
If successful, this could enable safer, less intense radiation therapy for some patients by allowing doctors to tailor treatment based on real-time HPV levels.
What could go wrong
This is a small, early-stage study focused on validating a new test, not on treatment outcomes. The method may not prove accurate enough to guide clinical decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * a patient with an oropharyngeal tumor indicated for curative radiation therapy or chemoradiotherapy * if radiation therapy or chemoradiotherapy was preceded by surgery, the patient may be enrolled if the lesion persists on imaging studies * the lesion must be a histologically confirmed squamous cell carcinoma with known p16 status * age ≥ 18 years * the subject must be willing and able to provide written informed consent for specimen collection * ability to communicate effectively with the investigator in the local language, and ability to understand and comply with the study requirements Exclusion Criteria: * previous induction chemotherapy * unknown p16 status, incomplete or inadequate histology-e.g., adenocarcinoma, melanoma, lymphoma, * previous radiation therapy to the oropharynx * palliative patients indicated for accelerated radiation therapy with a treatment duration of \< 5.5 weeks * age \< 18 years * pregnant or breastfeeding women * patients in the terminal stage of life * severe alcohol and/or drug abuse during treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Oropharyngeal carcinoma (OPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Head and Neck Neoplasms oropharyngeal carcinoma oropharynx cancer oropharynx squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Oropharyngeal carcinoma (OPC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Masaryk Memorial Cancer Institute

    RECRUITING

    Brno, Czech Republic, 65653, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.